β-catenin-IN-2|CAS 1458664-10-2|DC Chemicals

Cas No.:	1458664-10-2
Chemical Name:	beta-Catenin-IN-2
Synonyms:	beta-catenin-IN-2;4-(6-Fluoro-1H-benzo[d]imidazol-2-yl)-N,N-dimethylaniline;β-catenin-IN-2
SMILES:	FC1C([H])=C([H])C2=C(C=1[H])N([H])C(C1C([H])=C([H])C(=C([H])C=1[H])N(C([H])([H])[H])C([H])([H])[H])=N2
Formula:	C₁₅H₁₄FN₃
M.Wt:	255.2902
Purity:	>98%
Sotrage:	Powder-20°C3 years4°C2 yearsIn solvent-80°C6 months -20°C1 month

Description:	β-catenin-IN-2 is a potent β-catenin inhibitor, compound H1B1, extracted from patent US20150374662A1. β-catenin-IN-2 can be used for the study of colorectal cancer.
In Vitro:	β-catenin-IN-2 (10-40 μM) suppresses the transcriptional activity of the β-catenin/Tcf-4 in a dose-dependent manner in HCT116 cells[1].
References:	[1]. Ann Marie Bode, et al. Inhibitors of beta-catenin in treatment of colorectal cancer. Patent US20150374662A1.

Cat. No.	Product name	Field of application
DC70375	E722-2648	E722-2648 (Compound C-1) is a novel specific and competitive small molecule β-catenin/BCL9 interaction inhibitor with ITC KD of 1.05 uM and IC50 of 9 uM, blocks oncogenic Wnt signaling and disrupts cholesterol homeostasis in colorectal cancer.E722-2648 (Compound C-1) inhibited β-catenin/BCL9 complexes at concentrations as low as 1 uM in BCL9-dependent CRC cell lines, Colo320 and HCT116.E722-2648 (Compound C-1) inhibited the expression of bona fide downstream Wnt/β-catenin target genes, AXIN2 and CD44, in the β-catenin/BCL9-dependent CRC cell lines.E722-2648 (Compound C-1) disrupted cholesterol homeostasis via increased cholesterol esterification and lipid droplet accumulation.E722-2648 (Compound C-1) demonstrated antitumorigenic activity in CRC cell lines and xenograft mouse models.
DC46190	PRI-724	PRI-724 (C-82 prodrug, ICG-001 analog) is a potent and specific inhibitor that disrupts the interaction of β-catenin and CBP.
DC40956	β-catenin-IN-2	β-catenin-IN-2 is a potent β-catenin inhibitor, compound H1B1, extracted from patent US20150374662A1. β-catenin-IN-2 can be used for the study of colorectal cancer.
DC29001	CWP232228	CWP232228, a highly potent selective Wnt/β-catenin signaling inhibitor, antagonizes binding of β-catenin to T-cell factor (TCF) in the nucleus. CWP232228 suppresses tumor formation and metastasis without toxicity through the inhibition of the growth of breast and liver cancer stem cells (CSCs).
DC10976	E-7386	E-7386 (E7386) is a potent, orally active modulator of CBP/beta-catenin, disrupts the interaction and inhibits canonical Wnt signaling pathway /TCF reporter gene activity in LiCl-stimulated HEK-293 and MDA-MB-231 with IC50 of 55 and 73 nM, respectively.